Jia Xiu-Hong, Zhu Li-Ping, Li Jian-Chang, Wang Cui-Cui
Department of Pediatrics, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2013 Apr;15(4):268-72.
To investigate the expression of homeobox gene HOXA9 in the bone marrow mononuclear cells of children with acute leukemia (AL) and its clinical significance.
Forty-six children with AL were divided into acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) groups. Fifteen children with idiopathic thrombocytopenic purpura were selected as a control group. The mRNA expression of HOXA9 was measured by reverse transcription polymerase chain reaction (RT-PCR).
HOXA9 expression was detected in 63% of the 52 bone marrow samples from 46 AL children. The positive HOXA9 expression rate in the AML group was significantly higher than in the ALL and control groups (86% vs 35% and 13%; P<0.05). The mRNA expression of HOXA9 in the AML group was significantly higher than in the ALL and control groups (P<0.05). Among the children with AML, those with M5 AML had the highest HOXA9 mRNA level, followed by children with M4 AML and children with M1 and/or M2 AML, but HOXA9 expression was not detected in children with M3 AML. The high-risk subgroup of AML children had relatively high levels of HOXA9 expression. In the children with AML, the initial treatment subgroup had significantly higher positive HOXA9 expression rate and HOXA9 mRNA levels than in the remission subgroup and control group (P<0.05), but there were no significant differences between the latter two groups (P>0.05). The non-remission subgroup had significantly higher HOXA9 expression than the remission subgroup and control group (P<0.05).
High expression of HOXA9 is associated with the occurrence of AL, and its expression level is significantly higher in children with AML than in those with ALL. There is a positive correlation between the expression level of HOXA9 and the risk of childhood leukemia, and high expression of HOXA9 suggests poor prognosis. Therefore, HOXA9 can be used as one of the indices in the diagnosis, treatment and prognosis prediction of childhood AL.
探讨同源框基因HOXA9在急性白血病（AL）患儿骨髓单个核细胞中的表达及其临床意义。
将46例AL患儿分为急性髓系白血病（AML）组和急性淋巴细胞白血病（ALL）组。选取15例特发性血小板减少性紫癜患儿作为对照组。采用逆转录聚合酶链反应（RT-PCR）检测HOXA9的mRNA表达。
46例AL患儿的52份骨髓样本中，63%检测到HOXA9表达。AML组HOXA9阳性表达率显著高于ALL组和对照组（86%对35%和13%；P<0.05）。AML组HOXA9的mRNA表达显著高于ALL组和对照组（P<0.05）。在AML患儿中，M5型AML患儿的HOXA9 mRNA水平最高，其次是M4型AML患儿以及M1和/或M2型AML患儿，但M3型AML患儿未检测到HOXA9表达。AML患儿的高危亚组HOXA9表达水平相对较高。在AML患儿中，初始治疗亚组的HOXA9阳性表达率和HOXA9 mRNA水平显著高于缓解亚组和对照组（P<0.05），但后两组之间无显著差异（P>0.05）。未缓解亚组的HOXA9表达显著高于缓解亚组和对照组（P<0.05）。
HOXA9高表达与AL的发生有关，其表达水平在AML患儿中显著高于ALL患儿。HOXA9表达水平与儿童白血病风险呈正相关，HOXA9高表达提示预后不良。因此，HOXA9可作为儿童AL诊断、治疗及预后预测的指标之一。
